Lower Urinary Tract Dysfunction in the Central Nervous System Neurogenic Bladder and the Real-life Treatment Outcome of Botulinum Toxin A

Overview

Journal Tzu Chi Med J

Specialty General Medicine

Date 2024 Jul 12

PMID 38993829

Authors

Hann-Chorng Kuo

Affiliations

Soon will be listed here.

Abstract

Neurogenic lower urinary tract dysfunction (NLUTD) is common in patients with central nervous system (CNS) lesions. Cases of cerebrovascular accidents (CVA), Parkinson's disease, dementia, and other intracranial lesions develop poor bladder control with or without urinary difficulty due to loss of cortical perception of bladder filling sensation and poor coordination of urethral sphincter relaxation during reflex micturition. Patients with CNS lesions usually have overactive bladder (OAB) symptoms, including urgency, frequency, incontinence, voiding symptoms of dysuria, large postvoid residual volume, and retention. In elderly patients with severe CNS disease the OAB symptoms are usually difficult to adequately relieve by medical treatment, and thus, their quality of life is greatly. Botulinum toxin A (BoNT-A) is currently licensed and has been applied in patients with idiopathic and neurogenic OAB due to spinal cord injury or multiple sclerosis. However, the application of BoNT-A in the treatment of urinary incontinence due to NLUTD in chronic CNS lesions has not been well-documented. Although cohort studies and case series support BoNT-A treatment for neurogenic OAB, chronic urine retention after intravesical BoNT-A injection for OAB and exacerbated urinary incontinence after urethral BoNT-A injection for voiding dysfunction have greatly limited its application among patients with NLUTD due to CNS lesions. This article reviews the pathophysiology and clinical characteristics of NLUTD in patients with CNS lesions and the clinical effects and adverse events of BoNT-A injection for patients with NLUTD. A flowchart was created to outline the patient selection and treatment strategy for neurogenic OAB.

References

Kaviani A, Khavari R . Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am. 2017; 44(3):463-474. PMC: 5604875. DOI: 10.1016/j.ucl.2017.04.012. View

Brubaker L, Richter H, Visco A, Mahajan S, Nygaard I, Braun T . Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008; 180(1):217-22. PMC: 2597793. DOI: 10.1016/j.juro.2008.03.028. View

Kay G, Abou-Donia M, Messer Jr W, Murphy D, Tsao J, Ouslander J . Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2006; 53(12):2195-201. DOI: 10.1111/j.1532-5415.2005.00537.x. View

Ciofu I, Ceausu I, Chirca N, Persu C . Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity. Am J Ther. 2022; 29(5):e507-e511. DOI: 10.1097/MJT.0000000000001531. View

Zillioux J, Welk B, Suskind A, Gormley E, Goldman H . SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022; 41(8):1928-1933. DOI: 10.1002/nau.25037. View

Baron M, Peyronnet B, Auble A, Hascoet J, Castel-Lacanal E, Miget G . Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study. J Urol. 2018; 201(4):769-776. DOI: 10.1016/j.juro.2018.10.012. View

Berger Y, Blaivas J, DeLaRocha E, Salinas J . Urodynamic findings in Parkinson's disease. J Urol. 1987; 138(4):836-8. DOI: 10.1016/s0022-5347(17)43390-8. View

Tudor K, Sakakibara R, Panicker J . Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016; 263(12):2555-2564. DOI: 10.1007/s00415-016-8212-2. View

Kessler T, Danuser H, Schumacher M, Studer U, Burkhard F . Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn. 2005; 24(3):231-6. DOI: 10.1002/nau.20105. View

10.

Atamian A, Sichez P, Michel F, Bandelier Q, Fall M, Gaillet S . [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease]. Prog Urol. 2021; 31(7):430-438. DOI: 10.1016/j.purol.2021.01.004. View

11.

Chen S, Chuang Y, Wang C, Liao C, Kuo H . Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study. J Formos Med Assoc. 2022; 121(10):2101-2108. DOI: 10.1016/j.jfma.2022.04.004. View

12.

Kuo H . Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008; 27(8):793-6. DOI: 10.1002/nau.20606. View

13.

Blaivas J . Pathophysiology of lower urinary tract dysfunction. Urol Clin North Am. 1985; 12(2):215-24. View

14.

Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G . Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011; 186(3):960-4. DOI: 10.1016/j.juro.2011.04.071. View

15.

Peyronnet B, Lapitan M, Tzelves L, OConnor E, Riogh A, Manso M . Benefits and Harms of Conservative, Pharmacological, and Surgical Management Options for Women with Bladder Outlet Obstruction: A Systematic Review from the European Association of Urology Non-neurogenic Female LUTS Guidelines Panel. Eur Urol Focus. 2021; 8(5):1340-1361. DOI: 10.1016/j.euf.2021.10.006. View

16.

Lee H, Kuo H . Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery. Toxins (Basel). 2023; 15(3). PMC: 10057732. DOI: 10.3390/toxins15030221. View

17.

Wang C, Lee C, Hwang Y, Kuo H . Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Low Urin Tract Symptoms. 2021; 13(4):440-447. DOI: 10.1111/luts.12384. View

18.

Kuo H . OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects. Drugs Aging. 2015; 33(1):1-9. DOI: 10.1007/s40266-015-0335-0. View

19.

Sakakibara R, Hattori T, Yasuda K, Yamanishi T . Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci. 1996; 137(1):47-56. DOI: 10.1016/0022-510x(95)00322-s. View

20.

Lightner D, Gomelsky A, Souter L, Vasavada S . Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019; 202(3):558-563. DOI: 10.1097/JU.0000000000000309. View